• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Fentanyl combined with xylazine designated an emerging threat to the United States

April 13, 2023
Caitlin McCafferty, Editor

This veterinary tranquilizer has a growing role in overdose deaths across the country

Fentanyl adulterated or associated with xylazine was officially designated an emerging threat to the United States by Rahul Gupta, MD, MPH, FACP, MBA, director of the White House Office of National Drug Control Policy (ONDCP). This designation authority is being used for the first time since it was established by Congress in 2018.

“As a physician, I am deeply troubled about the devastating impact of the fentanyl-xylazine combination, and as President Biden’s drug policy advisor, I am immensely concerned about what this threat means for the nation,” said Gupta, in a White House press release.1 “By declaring xylazine combined with fentanyl as an emerging threat, we are being proactive in our approach to save lives and creating new tools for public health and public safety officials and communities across the nation.

"To parents, loved ones, community leaders, and those affected by xylazine use: I want you to know that help is on the way,” she continued.

According to the release,1 the ONDCP is required to monitor novel and evolving patterns of substance use, establish criteria to determine when a substance or combination of substances should be designated an emerging threat, and then declare emerging threats when the director deems appropriate based on the criteria.1 Published earlier this year, the criteria focuses on the geographic presence of the emerging threat and impact measured by metrics like overdoses in a year.

Advertisement

Gupta's decision to make this designation is because xylazine combined with fentanyl is illicitly being sold and has created significant and quickly worsening negative health consequences.1 Findings from the DEA include:2

  • Between 2020 and 2021, forensic laboratory identifications of xylazine rose in all 4 United States census regions, most notably in the South (193%) and the West (112%).
  • Xylazine-positive overdose deaths increased by 1127% in the South, 750% in the West, more than 500% in the Midwest, and more than 100% in the Northeast.

The Biden-Harries Administration will follow the designation by taking steps to publish a whole-of-government response that includes evidence-based prevention, treatment, and supply reduction, according to the White House. The federal government now has the power to put together resources to help counteract the illegal supply of xylazine combinations found across the US. The ONDCP will create an interagency working group to help create the national response plan, including comprehensive data systems, work on xylazine testing, strategies to reduce illicit supply, rapid research to understand the interactions between fentanyl and xylazine, and treatment and supportive care protocols.1

Additionally, on March 28, 2023, the Combating Illicit Xylazine Act was introduced to Congress in response to the drugs increasing presence on the street. The American Veterinary Medical Association (AVMA)-backed bill will help law enforcement by providing additional tools to trafficking xylazine while preserving a veterinarian’s ability to use xylazine legitimately.3 The AVMA has also issued a call to action, urging veterinary advocates to reach out to support the legislation to their members of congress.

References

  1. Biden-⁠Harris Administration Designates Fentanyl Combined with Xylazine as an Emerging Threat to the United States. News release. The White House. April 12, 2023. Accessed April 13, 2023. https://www.whitehouse.gov/ondcp/briefing-room/2023/04/12/biden-harris-administration-designates-fentanyl-combined-with-xylazine-as-an-emerging-threat-to-the-united-states/
  2. The Growing Threat of Xylazine and its Mixture with Illicit Drugs. Dea.gov. Accessed April 13, 2023. https://www.dea.gov/sites/default/files/2022-12/The%20Growing%20Threat%20of%20Xylazine%20and%20its%20Mixture%20with%20Illicit%20Drugs.pdf
  3. Illicit xylazine, fentanyl combination decreed ‘emerging threat’. News release. American Veterinary Medical Association. News release. American Veterinary Medical Association. April 12, 2023. Accessed April 13, 2023. https://www.avma.org/news/illicit-xylazine-fentanyl-combination-decreed-emerging-threat?utm_source=delivra&utm_medium=email&utm_campaign=todays-headlines-news

Related Content:

PharmacyBreaking News
FDA and European Union expand Mutual Recognition Agreement to include animal drugs
FDA and European Union expand Mutual Recognition Agreement to include animal drugs
Drug for acute onset of canine pancreatitis is launched on the US market
Drug for acute onset of canine pancreatitis is launched on the US market
Gene therapy demonstrates benefit to dogs with myxomatous mitral valve disease
Gene therapy demonstrates benefit to dogs with myxomatous mitral valve disease

Advertisement

Latest News

Can our Pride panel answer these LGBTQ+ trivia questions?

Creating inclusive spaces for the LGBTQ+ community in vet med

Happy Pride Month, Hill's launches Prescription Diet ONC Care, and more

CityVet Celina opens in Prosper, Texas

View More Latest News
Advertisement